nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Salivary hypersecretion—Epirubicin—liver cancer	0.00333	0.00333	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Sorafenib—liver cancer	0.00331	0.00331	CcSEcCtD
Gadoversetamide—Shock—Sorafenib—liver cancer	0.00326	0.00326	CcSEcCtD
Gadoversetamide—Nervous system disorder—Sorafenib—liver cancer	0.00325	0.00325	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Sorafenib—liver cancer	0.00325	0.00325	CcSEcCtD
Gadoversetamide—Skin disorder—Sorafenib—liver cancer	0.00322	0.00322	CcSEcCtD
Gadoversetamide—Neck pain—Doxorubicin—liver cancer	0.00322	0.00322	CcSEcCtD
Gadoversetamide—Anorexia—Sorafenib—liver cancer	0.00316	0.00316	CcSEcCtD
Gadoversetamide—Injection site reaction—Doxorubicin—liver cancer	0.00316	0.00316	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Epirubicin—liver cancer	0.00315	0.00315	CcSEcCtD
Gadoversetamide—Eructation—Doxorubicin—liver cancer	0.00312	0.00312	CcSEcCtD
Gadoversetamide—Ecchymosis—Epirubicin—liver cancer	0.0031	0.0031	CcSEcCtD
Gadoversetamide—Melaena—Doxorubicin—liver cancer	0.0031	0.0031	CcSEcCtD
Gadoversetamide—Salivary hypersecretion—Doxorubicin—liver cancer	0.00309	0.00309	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00302	0.00302	CcSEcCtD
Gadoversetamide—Hypertonia—Epirubicin—liver cancer	0.00301	0.00301	CcSEcCtD
Gadoversetamide—Dyspnoea—Sorafenib—liver cancer	0.00296	0.00296	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Doxorubicin—liver cancer	0.00292	0.00292	CcSEcCtD
Gadoversetamide—Dyspepsia—Sorafenib—liver cancer	0.00292	0.00292	CcSEcCtD
Gadoversetamide—Decreased appetite—Sorafenib—liver cancer	0.00288	0.00288	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Gadoversetamide—Ecchymosis—Doxorubicin—liver cancer	0.00287	0.00287	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Sorafenib—liver cancer	0.00286	0.00286	CcSEcCtD
Gadoversetamide—Fatigue—Sorafenib—liver cancer	0.00286	0.00286	CcSEcCtD
Gadoversetamide—Pain—Sorafenib—liver cancer	0.00283	0.00283	CcSEcCtD
Gadoversetamide—Constipation—Sorafenib—liver cancer	0.00283	0.00283	CcSEcCtD
Gadoversetamide—Hypertonia—Doxorubicin—liver cancer	0.00278	0.00278	CcSEcCtD
Gadoversetamide—Eye pain—Epirubicin—liver cancer	0.00276	0.00276	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Sorafenib—liver cancer	0.00271	0.00271	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Doxorubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Gadoversetamide—Increased appetite—Epirubicin—liver cancer	0.00265	0.00265	CcSEcCtD
Gadoversetamide—Urticaria—Sorafenib—liver cancer	0.00263	0.00263	CcSEcCtD
Gadoversetamide—Abdominal pain—Sorafenib—liver cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Body temperature increased—Sorafenib—liver cancer	0.00262	0.00262	CcSEcCtD
Gadoversetamide—Eye pain—Doxorubicin—liver cancer	0.00255	0.00255	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Epirubicin—liver cancer	0.00255	0.00255	CcSEcCtD
Gadoversetamide—Hyponatraemia—Epirubicin—liver cancer	0.0025	0.0025	CcSEcCtD
Gadoversetamide—Diplopia—Epirubicin—liver cancer	0.00249	0.00249	CcSEcCtD
Gadoversetamide—Increased appetite—Doxorubicin—liver cancer	0.00245	0.00245	CcSEcCtD
Gadoversetamide—Hypersensitivity—Sorafenib—liver cancer	0.00244	0.00244	CcSEcCtD
Gadoversetamide—Face oedema—Epirubicin—liver cancer	0.00241	0.00241	CcSEcCtD
Gadoversetamide—Asthenia—Sorafenib—liver cancer	0.00238	0.00238	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Doxorubicin—liver cancer	0.00236	0.00236	CcSEcCtD
Gadoversetamide—Pruritus—Sorafenib—liver cancer	0.00235	0.00235	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Epirubicin—liver cancer	0.00234	0.00234	CcSEcCtD
Gadoversetamide—Hyponatraemia—Doxorubicin—liver cancer	0.00232	0.00232	CcSEcCtD
Gadoversetamide—Diplopia—Doxorubicin—liver cancer	0.00231	0.00231	CcSEcCtD
Gadoversetamide—Dry skin—Epirubicin—liver cancer	0.00228	0.00228	CcSEcCtD
Gadoversetamide—Diarrhoea—Sorafenib—liver cancer	0.00227	0.00227	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Epirubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Face oedema—Doxorubicin—liver cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Muscular weakness—Epirubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Dizziness—Sorafenib—liver cancer	0.00219	0.00219	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Doxorubicin—liver cancer	0.00216	0.00216	CcSEcCtD
Gadoversetamide—Asthma—Epirubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Influenza—Epirubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Dysphagia—Epirubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Gadoversetamide—Dry skin—Doxorubicin—liver cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Vomiting—Sorafenib—liver cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Rash—Sorafenib—liver cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Dermatitis—Sorafenib—liver cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Headache—Sorafenib—liver cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Doxorubicin—liver cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Muscular weakness—Doxorubicin—liver cancer	0.00203	0.00203	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00203	0.00203	CcSEcCtD
Gadoversetamide—Dysuria—Epirubicin—liver cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Asthma—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Influenza—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Dysphagia—Doxorubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Nausea—Sorafenib—liver cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Epirubicin—liver cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Pneumonia—Epirubicin—liver cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Conjunctivitis—Epirubicin—liver cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Urinary tract infection—Epirubicin—liver cancer	0.00187	0.00187	CcSEcCtD
Gadoversetamide—Dysuria—Doxorubicin—liver cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Haematuria—Epirubicin—liver cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Epistaxis—Epirubicin—liver cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Sinusitis—Epirubicin—liver cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Doxorubicin—liver cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Pneumonia—Doxorubicin—liver cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Haemoglobin—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Rhinitis—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Conjunctivitis—Doxorubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Urinary tract infection—Doxorubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Haemorrhage—Epirubicin—liver cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Epirubicin—liver cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Pharyngitis—Epirubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Oedema peripheral—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Haematuria—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Urethral disorder—Epirubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Epistaxis—Doxorubicin—liver cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Sinusitis—Doxorubicin—liver cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Erythema multiforme—Epirubicin—liver cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Eye disorder—Epirubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Gadoversetamide—Tinnitus—Epirubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Gadoversetamide—Haemoglobin—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Cardiac disorder—Epirubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Flushing—Epirubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Rhinitis—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Haemorrhage—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Doxorubicin—liver cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Pharyngitis—Doxorubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Doxorubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Oedema peripheral—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Angiopathy—Epirubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Urethral disorder—Doxorubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Immune system disorder—Epirubicin—liver cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Chills—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Arrhythmia—Epirubicin—liver cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Mental disorder—Epirubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Erythema multiforme—Doxorubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Erythema—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Malnutrition—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Gadoversetamide—Eye disorder—Doxorubicin—liver cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Tinnitus—Doxorubicin—liver cancer	0.00149	0.00149	CcSEcCtD
Gadoversetamide—Flushing—Doxorubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Cardiac disorder—Doxorubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Flatulence—Epirubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Tension—Epirubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Dysgeusia—Epirubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Nervousness—Epirubicin—liver cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Back pain—Epirubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Gadoversetamide—Angiopathy—Doxorubicin—liver cancer	0.00145	0.00145	CcSEcCtD
Gadoversetamide—Muscle spasms—Epirubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Immune system disorder—Doxorubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Doxorubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Chills—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Arrhythmia—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Gadoversetamide—Vision blurred—Epirubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Mental disorder—Doxorubicin—liver cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Epirubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Erythema—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Malnutrition—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Agitation—Epirubicin—liver cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Flatulence—Doxorubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Tension—Doxorubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Dysgeusia—Doxorubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Malaise—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Nervousness—Doxorubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Vertigo—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Syncope—Epirubicin—liver cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Back pain—Doxorubicin—liver cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Muscle spasms—Doxorubicin—liver cancer	0.00134	0.00134	CcSEcCtD
Gadoversetamide—Palpitations—Epirubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Loss of consciousness—Epirubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Gadoversetamide—Cough—Epirubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Vision blurred—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Convulsion—Epirubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Hypertension—Epirubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Doxorubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Chest pain—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Arthralgia—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Myalgia—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Agitation—Doxorubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Gadoversetamide—Anxiety—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Gadoversetamide—Discomfort—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Malaise—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Dry mouth—Epirubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Vertigo—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Syncope—Doxorubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Confusional state—Epirubicin—liver cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Palpitations—Doxorubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Epirubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Oedema—Epirubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Loss of consciousness—Doxorubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Cough—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Shock—Epirubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Gadoversetamide—Convulsion—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Nervous system disorder—Epirubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Epirubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Hypertension—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Tachycardia—Epirubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Skin disorder—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Epirubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Myalgia—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Chest pain—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Arthralgia—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Anxiety—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Discomfort—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Anorexia—Epirubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Dry mouth—Doxorubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Hypotension—Epirubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Confusional state—Doxorubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Oedema—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Shock—Doxorubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Nervous system disorder—Doxorubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Doxorubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Insomnia—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Tachycardia—Doxorubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Skin disorder—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Paraesthesia—Epirubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Dyspnoea—Epirubicin—liver cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Somnolence—Epirubicin—liver cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Anorexia—Doxorubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Dyspepsia—Epirubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Decreased appetite—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Hypotension—Doxorubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Fatigue—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Gadoversetamide—Pain—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Constipation—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Insomnia—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Paraesthesia—Doxorubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Dyspnoea—Doxorubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Feeling abnormal—Epirubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Somnolence—Doxorubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Epirubicin—liver cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Dyspepsia—Doxorubicin—liver cancer	0.000998	0.000998	CcSEcCtD
Gadoversetamide—Decreased appetite—Doxorubicin—liver cancer	0.000985	0.000985	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000979	0.000979	CcSEcCtD
Gadoversetamide—Fatigue—Doxorubicin—liver cancer	0.000977	0.000977	CcSEcCtD
Gadoversetamide—Urticaria—Epirubicin—liver cancer	0.000973	0.000973	CcSEcCtD
Gadoversetamide—Pain—Doxorubicin—liver cancer	0.000969	0.000969	CcSEcCtD
Gadoversetamide—Constipation—Doxorubicin—liver cancer	0.000969	0.000969	CcSEcCtD
Gadoversetamide—Abdominal pain—Epirubicin—liver cancer	0.000968	0.000968	CcSEcCtD
Gadoversetamide—Body temperature increased—Epirubicin—liver cancer	0.000968	0.000968	CcSEcCtD
Gadoversetamide—Feeling abnormal—Doxorubicin—liver cancer	0.000934	0.000934	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000927	0.000927	CcSEcCtD
Gadoversetamide—Hypersensitivity—Epirubicin—liver cancer	0.000903	0.000903	CcSEcCtD
Gadoversetamide—Urticaria—Doxorubicin—liver cancer	0.0009	0.0009	CcSEcCtD
Gadoversetamide—Body temperature increased—Doxorubicin—liver cancer	0.000896	0.000896	CcSEcCtD
Gadoversetamide—Abdominal pain—Doxorubicin—liver cancer	0.000896	0.000896	CcSEcCtD
Gadoversetamide—Asthenia—Epirubicin—liver cancer	0.000879	0.000879	CcSEcCtD
Gadoversetamide—Pruritus—Epirubicin—liver cancer	0.000867	0.000867	CcSEcCtD
Gadoversetamide—Diarrhoea—Epirubicin—liver cancer	0.000838	0.000838	CcSEcCtD
Gadoversetamide—Hypersensitivity—Doxorubicin—liver cancer	0.000835	0.000835	CcSEcCtD
Gadoversetamide—Asthenia—Doxorubicin—liver cancer	0.000813	0.000813	CcSEcCtD
Gadoversetamide—Dizziness—Epirubicin—liver cancer	0.00081	0.00081	CcSEcCtD
Gadoversetamide—Pruritus—Doxorubicin—liver cancer	0.000802	0.000802	CcSEcCtD
Gadoversetamide—Vomiting—Epirubicin—liver cancer	0.000779	0.000779	CcSEcCtD
Gadoversetamide—Diarrhoea—Doxorubicin—liver cancer	0.000776	0.000776	CcSEcCtD
Gadoversetamide—Rash—Epirubicin—liver cancer	0.000772	0.000772	CcSEcCtD
Gadoversetamide—Dermatitis—Epirubicin—liver cancer	0.000772	0.000772	CcSEcCtD
Gadoversetamide—Headache—Epirubicin—liver cancer	0.000767	0.000767	CcSEcCtD
Gadoversetamide—Dizziness—Doxorubicin—liver cancer	0.00075	0.00075	CcSEcCtD
Gadoversetamide—Nausea—Epirubicin—liver cancer	0.000728	0.000728	CcSEcCtD
Gadoversetamide—Vomiting—Doxorubicin—liver cancer	0.000721	0.000721	CcSEcCtD
Gadoversetamide—Rash—Doxorubicin—liver cancer	0.000715	0.000715	CcSEcCtD
Gadoversetamide—Dermatitis—Doxorubicin—liver cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Headache—Doxorubicin—liver cancer	0.00071	0.00071	CcSEcCtD
Gadoversetamide—Nausea—Doxorubicin—liver cancer	0.000673	0.000673	CcSEcCtD
